ラクオリア創薬(株)
株価チャート
2026/07/30 更新株価トレンド
2026/07/30 更新株価・取引詳細
2026/07/30 更新株価
取引
財務パフォーマンス
2026/07/26 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥29億 | ¥19億 | ¥31億 | ¥40億 |
| 売上総利益 | ¥27億 | ¥17億 | ¥25億 | ¥33億 |
| 営業利益 | ¥9億 | -¥3億 | -¥2億 | ¥5億 |
| 経常利益 | ¥9億 | -¥3億 | -¥3億 | ¥5億 |
| 当期純利益 | ¥7億 | -¥3億 | -¥5億 | ¥3億 |
| EPS | ¥34.47 | -¥14.98 | -¥22.87 | - |
| 営業利益率 | 29.69% | -17.74% | -6.87% | 12.15% |
| 貸借対照表 | ||||
| 総資産 | ¥63億 | ¥69億 | ¥97億 | ¥105億 |
| 純資産 | ¥55億 | ¥61億 | ¥56億 | ¥69億 |
| 総負債 | ¥8億 | ¥8億 | ¥41億 | ¥36億 |
| 現金 | ¥37億 | ¥37億 | ¥33億 | ¥32億 |
| 有利子負債 | ¥2億 | ¥4億 | ¥35億 | ¥29億 |
| 自己資本比率 | 87.84% | 89.06% | 57.69% | 65.59% |
| D/Eレシオ | 0.04 | 0.06 | 0.62 | 0.42 |
| キャッシュフロー | ||||
| 営業CF | ¥15億 | -¥7億 | ¥2億 | -¥4億 |
| 投資CF | -¥0億 | -¥1億 | -¥37億 | ¥1億 |
| 財務CF | -¥0億 | ¥8億 | ¥30億 | ¥4億 |
| フリーCF | ¥14億 | -¥9億 | ¥1億 | -¥4億 |
| 効率性 | ||||
| ROE | 13.16% | -5.29% | -8.89% | 3.96% |
| ROA | 11.56% | -4.71% | -5.13% | 2.60% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
